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Abstract
Background: Despite documented benefits of lipid-lowering treatment in women, a considerable number are
undertreated, and fewer achieve treatment targets vs. men.
Methods: Data were combined from 27 double-blind, active or placebo-controlled studies that randomized adult
hypercholesterolemic patients to statin or statin+ezetimibe. Consistency of treatment effect among men
(n = 11,295) and women (n = 10,499) was assessed and percent of men and women was calculated to evaluate
the between-treatment ability to achieve specified treatment levels between sexes.
Results: Baseline lipids and hs-CRP were generally higher in women vs. men. Between-treatment differences were
significant for both sexes (all p < 0.001 except apolipoprotein A-I in men = 0.0389). Men treated with ezetimibe
+statin experienced significantly greater changes in LDL-C (p = 0.0066), non-HDL-C, total cholesterol, triglycerides,
HDL-C, apolipoprotein A-I (all p < 0.0001) and apolipoprotein B (p = 0.0055) compared with women treated with
ezetimibe+statin. The odds of achieving LDL-C < 100 mg/dL, apolipoprotein B < 90 mg/dL and the dual target
[LDL-C < 100 mg/dL & apoliprotein B < 90 mg/dL] was significantly greater for women vs. men and the odds of
achieving hs-CRP < 1 and < 2 mg/L and dual specified levels of [LDL-C < 100 mg/dL and hs-CRP < 2 mg/L] were
significantly greater for men vs. women. Women reported significantly more gall-bladder-related, gastrointestinal-
related, and allergic reaction or rash-related adverse events (AEs) vs. men (no differences between treatments). Men
reported significantly more CK elevations (no differences between treatments) and hepatitis-related AEs vs. women
(significantly more with ezetimibe+simvastatin vs. statin).
Conclusions: These results suggest that small sex-related differences may exist in response to lipid-lowering
treatment and achievement of specified lipid and hs-CRP levels, which may have implications when managing
hypercholesterolemia in women.
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Background
The average lifetime risk for cardiovascular disease
(CVD) in women is very high, approaching 1 in 2 [1].
Accordingly, the 2011 update to the Guidelines for Car-
diovascular Disease Prevention in Women asserts that
nearly all women are at risk for CVD and stresses the
importance of CVD prevention and appropriate treat-
ment based on appropriate risk assessment [2]. In addi-
tion, the new guidelines lowered the threshold defining
high risk to > 10% 10-year risk for CVD. With few
exceptions, recommendations for preventive measures
for CVD are similar in men and women. For cardiovas-
cular risk reduction, the primary target for men and
women is low-density lipoprotein cholesterol (LDL-C)
[2,3]. Optimal levels of high-density lipoprotein choles-
terol (HDL-C), non-HDL-C, and triglycerides have also
been recommended for women [2]. In the general popu-
lation attainment of recommended lipid levels is subop-
timal, and fewer women achieve recommended lipid
levels compared with men [4]. Even though women are
less likely to be recruited in clinical trials [5,6], there is
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treatment in both sexes [2,7]. Despite this, a consider-
able number of women are undertreated, possibly due
to perceived lower risk for CVD in women [2].
Findings from the Women’s Health Initiative and the
Heart and Estrogen/Progestin Replacement Study under-
score the importance of evidence-based practice for
CVD prevention in women [8,9]. Elucidation of sex-
related tolerability and efficacy of specific lipid-lowering
treatments may help provide perspective for evidence-
based decision making, tailor preventive interventions
based on individual risk and benefit, and increase the
number of patients attaining individual treatment goals.
The objectives of this analysis were to assess sex-related
tolerability and lipid-altering efficacy and achievement
of specified lipid and high-sensitivity C-reactive protein
(hs-CRP) levels in men and women treated with statin +
ezetimibe or statin monotherapy in a broad, pooled
database of greater than 21,000 patients.
Methods
Data were combined from 27 double-blind, active- or
placebo-controlled efficacy studies that randomized
adult hypercholesterolemic patients to statin alone or
statin plus ezetimibe. Studies were conducted from 1999
to 2008 by Merck Research Laboratories to ensure full
access to individual patient data (Table 1). Studies with
cross-over design, extension studies, studies still
ongoing, outcome or imaging studies, studies in which
ezetimibe was used as monotherapy or in combination
with other non-statin lipid-lowering drugs (e.g., fenofi-
brate, niacin), adolescent or pediatric patient studies,
and studies focusing on patients with sitosterolemia,
homozygous familial hypercholesterolemia, aortic steno-
sis, or chronic kidney disease were not included in the
analyses.
Specific inclusion criteria for the individual studies
have been previously published (see citations in Table 1).
As guidelines changed over time, there was no single
lipid entry criterion that applied to all studies. In general,
a patient was considered hypercholesterolemic if LDL-C
levels were above guideline-recommended levels accord-
ing to risk. The range of baseline LDL-C inclusion levels
in the studies was > 70 mg/dL to < 250 mg/dL (Table 1).
Ezetimibe add-on treatments included ezetimibe 10 mg
added to atorvastatin 10-80 mg, ezetimibe 10 mg added
to lovastatin 10-40 mg, ezetimibe 10 mg added to pravas-
tatin 10-40 mg, ezetimibe 10 mg added to simvastatin
10-80 mg, and ezetimibe 10 mg added to ongoing statin
dose. Statin monotherapy included atorvastatin 10-80
mg, lovastatin 10-40 mg, pravastatin 10-40 mg, rosuvas-
tatin 10-40 mg, and simvastatin 10-80 mg.
Drug-naïve patients were randomized to receive dou-
ble-blind ezetimibe/statin [ezetimibe/simvastatin
combination tablet (10/10, 10/20, 10/40 or 10/80 mg) or
ezetimibe 10 mg co-administered with: simvastatin 10,
20, 40 or 80 mg; lovastatin 10, 20 or 40 mg; pravastatin
10, 20 or 40 mg or atorvastatin 10, 20, 40 or 80 mg] or
statin alone (simvastatin 10, 20, 40 and 80 mg; lovastatin
10, 20 and 40 mg; pravastatin 10, 20 and 40 mg; ator-
vastatin 10, 20, 40 and 80 mg or rosuvastatin 10, 20 or
40 mg) for up to 12 weeks. In the add-on therapy stu-
dies, statin-treated patients were randomized to receive
double-blind placebo or ezetimibe 10 mg administered
in combination with their ongoing, previously pre-
scribed, open-label statin (simvastatin 20 or 40 mg or
atorvastatin 10, 20, or 40 mg) or doubling the statin
dose (to simvastatin 40 or 80 mg or to atorvastatin 20,
40, or 80 mg) for up to 24 weeks. In switch-therapy stu-
dies, statin-treated patients were switched from their
ongoing, previously prescribed, open-label statin (sim-
vastatin 20 or 40 mg; pravastatin 40 mg; fluvastatin 80
mg; atorvastatin 10 or 20 mg; or rosuvastatin 5 mg) to
receive double-blind ezetimibe/statin (ezetimibe/simvas-
tatin combination tablet 10/20 or 10/40 mg) or statin
alone (atorvastatin 20 mg or rosuvastatin 10 mg) for up
to 6 weeks.
Efficacy Measures
The % change from baseline to study end in LDL-C,
HDL-C, non-HDL-C, total cholesterol, triglycerides,
apolipoprotein B, apolipoprotein A-I; ratios for total
cholesterol/HDL-C, LDL-C/HDL-C, apolipoprotein B/
apolipoprotein A-I, non-HDL-C/HDL-C; and hs-CRP
were measured. In addition, the % of patients achieving
the single specified targets of LDL-C < 100 mg/dL, non-
HDL-C < 130 mg/dL, apolipoprotein B < 90 mg/dL, and
specified levels of hs-CRP < 2 mg/L and < 1 mg/L as
well as the dual specified levels of LDL-C < 100 mg/dL
& non-HDL-C < 130 mg/dL, LDL-C < 100 mg/dL &
apolipoprotein B < 90 mg/dL, LDL-C < 100 mg/dL &
hs-CRP < 2 mg/L, LDL-C < 100 mg/dL & hs-CRP < 1
mg/L were calculated.
Laboratory methods
Analysis of samples for all clinical laboratory values
were performed at a certified central laboratory accord-
ing to standards specified by the National Heart Lung
and Blood Institute and Centers for Disease Control and
Prevention. LDL-C levels were calculated using the Frie-
dewald equation or measured directly using the beta-
quantification method if triglycerides were > 400 mg/dL.
Statistics
Efficacy was assessed in a modified version of the intent-
to-treat population, which includes all randomized
patients who had baseline values, had taken at least 1
dose of study medication, and had 1 or more post-
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Protocol Number
[citation]
Treatment Randomized to
Statin
Randomized to Statin+EZ Inclusion Criteria
Men
(N = 5389)
Women
(N = 5142)
Men
(N = 6140)
Women
(N = 5607)
Min LDL-C Max LDL-C
005
[37]
PBO, EZ
EZ+S 10, 20, 40, 80
S 10, 20, 40, 80
172 177 169 184 145 mg/dL 250 mg/dL
011
[38]
PBO, EZ
S 10, 20, 40, 80
EZ+S 10, 20, 40, 80
110 153 126 148 145 mg/dL 250 mg/dL
021
[15]
S2 0+E Z
Doubling S to 40
61 49 62 42 101 mg/dL not specified
023
[25]
S2 0 ,
EZ+S 10, 20, 40
158 95 292 165 130 mg/dL not specified
025
[39]
A1 0
EZ + S 10, 20
131 131 279 247 not at LDL-C goal as defined by NCEP ATP III
030
[40]
A1 0+E Z
Doubling A to 20
171 145 159 146 130 mg/dL not specified
038
[11]
PBO, EZ
EZ/S 10, 20, 40, 80
S 10, 20, 40, 80
307 315 296 313 145 mg/dL 250 mg/dL
040
[18]
Ongoing statin + PBO
Ongoing statin + EZ
510 500 1073 947 not at LDL-C goal as defined by NCEP ATP III
051
[41]
EZ/S 10, 20, 40, 80
A 10, 20, 40, 80
498 453 496 455 not at LDL-C goal as defined by NCEP ATP III
058
[42]
EZ/S 10, 20, 40, 80
R 10, 20, 40
624 857 678 800 145 mg/dL 250 mg/dL
077
[43]
EZ/S 20, 40
A 10, 20, 40
361 374 221 273 100 mg/dL not specified
079
[12]
A2 0+E Z
Doubling to A 40
49 49 58 40 100 mg/dL 160 mg/dL
090
[16]
A4 0+E Z
Doubling to A 80
178 113 173 115 70 mg/dL 160 mg/dL
107
[20]
EZ/S 20, 40
A 10, 20, 40
379 307 266 191 70 mg/dL
100 mg/dL
not specified
112
[22]
A1 0+E Z
A 20/40
249 277 241 286 70 mg/dL
100 mg/dL
160 mg/dL
679
[44]
PBO, EZ
L 10, 20, 40
EZ+L 10, 20, 40
88 132 86 106 145 mg/dL 250 mg/dL
691
[17]
PBO, EZ
P 10, 20, 40
EZ+P 10, 20, 40
101 104 83 121 145 mg/dL 250 mg/dL
692
[45]
PBO, EZ
A 10, 20, 40, 80
EZ+A 10, 20, 40, 80
95 153 107 148 145 mg/dL 250 mg/dL
700
[46]
S2 0+E Z
Double S to 40
19 15 33 33 130 mg/dL not specified
801
[23]
S 10, 20 + PBO
S 10, 20 + EZ
158 52 145 63 101 mg/dL 160 mg/dL
802
[47]
S 10, 20 + PBO
S 10, 20 + EZ
124 57 124 57 101 mg/dL 160 mg/dL
803/804
[24]
A 10, 20 + PBO
A 10, 20 + EZ
157 73 153 67 101 mg/dL 160 mg/dL
806
[48]
EZ/S 20
Doubling to A 20
128 86 141 80 101 mg/dL 160 mg/dL
807
[49]
EZ/S 20, 40
Doubling to A 20
108 111 224 218 not specified not specified
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patients as treated; however, laboratory adverse experi-
ences were analyzed in patients who had at least 1 post-
baseline assessment.
Consistency of treatment effect among men and
women was tested with analysis of covariance with
terms for treatment, first-/second-line lipid-lowering
therapy status, race, sex, coronary heart disease (CHD),
statin potency, age, body mass index, baseline LDL-C,
baseline HDL-C, baseline triglycerides, baseline response
variable, diabetes, trial within first-/second-line lipid-
lowering therapy status, treatment by first-/second-line
lipid-lowering therapy status, and treatment by sex
interactions. Statistical tests were two-sided and a p-
value of less than 0.05 was considered significant. How-
ever, due to the large population size, even very small
differences may be statistically significant, although not
clinically relevant. Therefore, inferential statistics were
not included for baseline values.
Statin potency was defined on the basis of LDL-C
reduction as low potency: simvastatin 10 mg, lovastatin
10-20 mg, pravastatin 10-20 mg, fluvastatin 10-40 mg,
and cerivastatin 0.2-0.3 mg; medium potency: simvasta-
tin 20-40 mg, atorvastatin 10-20 mg, lovastatin 40-80
mg, pravastatin 40-80 mg, fluvastatin 80-160 mg, ceri-
vastatin 0.4-0.8 mg, and rosuvastatin 5 mg; high
potency: simvastatin 80 mg, atorvastatin 40-80 mg, rosu-
vastatin 10-40 mg. The % of men and women, adjusted
odds ratios, and 95% confidence intervals (CIs) were cal-
culated using a logistic model with terms for first-/sec-
ond-line therapy, gender, treatment, and baseline value
to evaluate the between-treatment ability to achieve spe-
cified treatment levels in the full cohort and with terms
for first-/second-line therapy, treatment, and baseline
value in each sex subgroup. No adjustments were made
for multiplicity. Due to the large population size, the
results of these analyses should be interpreted with cau-
tion, since statistical significance may not always imply
clinical significance.
Results
A total of 22,231 patients were included in the safety
analysis and 21,794 patients were included in the modi-
fied intent-to-treat population for the efficacy analysis.
Subjects received the following active treatment regi-
mens during the studies: simvastatin: n = 2148; atorvas-
tatin: n = 4433; rosuvastatin: n = 1725; lovastatin: n =
220; pravastatin: n = 205; unspecified statin: n = 1577;
ezetimibe+simvastatin: n = 2372; ezetimibe+atorvastatin:
n = 4226; ezetimibe+rosuvastatin: n = 1723; ezetimibe
+lovastatin: n = 192; ezetimibe+pravastatin: n = 205;
ezetimibe+unspecified statin: n = 2760 (Table 1).
Baseline demographics were generally similar,
although risk factors differed somewhat between the
sexes: More women vs. men had body mass index ≥30
kg/mg
2, more women vs. men had metabolic syndrome
or diabetes mellitus, more men vs. women had CHD,
and at study entry, more men vs. women were being
treated with ongoing statin therapy (Table 2). Baseline
lipid and hs-CRP levels were generally higher in women
compared with men, except for lipid ratios, which were
generally similar between sexes (Table 2).
As seen in the individual studies, the overall popula-
tion demonstrated significant reductions in LDL-C, non-
HDL-C, triglycerides, apolipoprotein B, and hs-CRP. Sig-
nificantly greater reductions were observed in subjects
treated with combination statin + ezetimibe vs. statin
monotherapy (all p < 0.0001; data not shown). All
between-treatment differences were statistically signifi-
cant for both sexes (all p < 0.001 except apolipoprotein
A-I in men = 0.0389; Figure 1). Lipid responses to sta-
tins were similar for both sexes; however, men who
received ezetimibe + statin combination experienced a
significantly greater change in LDL-C (p = 0.0066), non-
HDL-C, total cholesterol, triglycerides, HDL-C, apolipo-
protein A-I (all p < 0.0001) and apolipoprotein B (p =
0.0055) compared with women who received ezetimibe
+ statin combination (Figure 1), although these differ-
ences were small (≤2%) and the clinical relevance could
be debated. There was no significant effect of sex on the
changes in the lipid ratios or hs-CRP (all p > 0.05; Fig-
ure 1).
Figures 2 and 3 show the percentage of patients
achieving single and dual lipid and hs-CRP levels by sex.
When comparing men vs. women, the odds of achieving
LDL-C < 100 mg/dL, apolipoprotein B < 90 mg/dL and
the dual target [LDL-C < 100 mg/dL & apolipoprotein B
< 90 mg/dL] was significantly greater for women,
Table 1 Characteristics of studies included in the pooled analyses (Continued)
809
[13]
EZ/S 20
R10
185 119 185 129 100 mg/dL 160 mg/dL
2173/2246
[14]
Ongoing statin + EZ
Ongoing statin+ PBO
221 169 222 157 not at LDL-C goal as defined by NCEP ATP III
3377
[21]
EZ+S 20
S2 0
47 76 48 76 145 mg/dL 250 mg/dL
A = atorvastatin; EZ = ezetimibe; L = lovastatin; LDL-C = low-density lipoprotein cholesterolemia; NCEP ATP III = National Cholesterol Education Program Adult
Treatment Panel III; P = pravastatin = S = simvastatin.
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Page 4 of 11although the differences were small (Table 3). Conver-
sely, the odds of achieving hs-CRP < 1 mg/L, hs-CRP <
2 mg/L and dual specified levels of [LDL-C < 100 mg/
dL and hs-CRP < 2 mg/L] were significantly greater for
men than for women, and those differences were also
small (Table 3). Of note, the odds ratios and 95% confi-
dence intervals (Table 3) are calculated from the model
with terms for first-/second-line therapy, sex, treatment
and baseline LDL-C. The baseline is adjusted and the
statistics are comparing all women versus all men
attaining specified targets, and not by treatment group.
When comparing by treatment group in both men and
women, the odds of achieving all single and dual speci-
fied targets was greater in subjects treated with the
combination statin + ezetimibe compared with statin
monotherapy (Table 4).
A summary of adverse events is listed in Table 5. When
comparing the full cohort, both treatments had generally
similar tolerability and safety profiles (i.e., there were no
between-treatment differences in adverse events, liver
enzymes, or creatine kinase elevations). There were
significantly more alanine aminotransferase (ALT) eleva-
tions ≥3 × upper limit of normal reported in the combina-
tion treatment group compared with statin monotherapy,
and although there was no statistically significant effect of
sex, this difference was primarily driven by elevations in
males (Table 5). When comparing the sexes, women
reported significantly more adverse events (i.e., ≥1 adverse
event), drug-related adverse events, gall-bladder-related
adverse events, gastrointestinal-related adverse events,
allergic reaction or rash-related adverse events; and more
women discontinued due to adverse events and drug-
related adverse events, although there were no significant
differences between treatments (Table 5). Compared with
women, men reported significantly more creatine kinase
elevations ≥ 10 × upper limit of normal (no differences
between treatments) and hepatitis-related adverse events,
of which there were significantly more in the combination
group vs. the statin monotherapy group (Table 5). There
were 7 cases of myopathy reported, with no significant dif-
ferences between treatments or sexes in their occurrence,
and no cases of rhabdomyolysis reported (Table 5). A total
Table 2 Baseline demographics, risk factors and clinical characteristics
Male Female
Statin
(n = 5279)
Statin + EZ
(n = 6016)
Statin
(n = 5029)
Statin + EZ
(n = 5470)
Mean age, years (SD) 58.4 (11.22) 59.2 (11.14) 60.0 (11.23) 60.7 (11.01)
Age, n (%)
< 65 years 3556 (67.4) 3909 (65.0) 3126 (62.2) 3341 (61.1)
65-74 years 1361 (25.8) 1614 (26.8) 1457 (29.0) 1557 (28.5)
≥75 years 362 (6.9) 493 (8.2) 446 (8.9) 572 (10.5)
Caucasian, n (%) 4549 (86.2) 5187 (86.2) 4141 (82.3) 4519 (82.6)
BMI < 30 kg/m
2 (%) 3287 (63.2) 3728 (62.8) 2721 (55.0) 3056 (56.7)
CHD, n (%) 2129 (40.3) 2614 (43.5) 1181 (23.5) 1501 (27.5)
Diabetes, n (%) 1491 (28.2) 1732 (28.8) 1591 (31.6) 1727 (31.6)
Metabolic syndrome 1912 (46.5) 2112 (45.8) 2321 (54.7) 2406 (53.6)
Ongoing Statin*, n (%) 2271 (43.0) 2935 (48.8) 1780 (35.4) 2310 (42.2)
Least squares mean (SD) (n = 5279) (n = 6016) (n = 5029) (n = 5470)
LDL-C (mg/dL) 147.0 (40.3) 144.4 (39.8) 156.4 (41.7) 154.2 (42.5)
HDL-C (mg/dL) 45.8 (10.5) 45.7 (10.3) 53.4 (12.7) 53.7 (13.0)
non-HDL-C (mg/dL) 180.2 (44.5) 177.5 (44.0) 190.1 (45.8) 187.6 (46.4)
TC (mg/dL) 226.0 (44.0) 223.2 (43.6) 243.6 (45.7) 241.3 (46.2)
Triglycerides (mg/dL)
‡ 150.0 (88.1) 151.0 (87.9) 156.5 (90.2) 154.0 (90.7)
Apo B (mg/dL) 142.5 (32.7) 141.3 (32.3) 147.9 (34.0) 146.4 (34.4)
Apo AI (mg/dL) 146.3 (23.2) 146.4 (23.8) 164.2 (27.5) 165.0 (28.0)
hs-CRP (mg/L)
‡ 1.8 (2.7) 1.8 (2.7) 2.7 (4.1) 2.8 (4.1)
non-HDL-C/HDL-C 4.1 (1.5) 4.1 (1.4) 3.8 (1.4) 3.7 (1.4)
Apo B/Apo AI 1.0 (0.3) 1.0 (0.3) 0.9 (0.3) 0.9 (0.3)
LDL-C/HDL-C 3.4 (1.2) 3.3 (1.2) 3.1 (1.1) 3.0 (1.1)
TC/HDL-C 5.2 (1.5) 5.1 (1.4) 4.8 (1.4) 4.7 (1.4)
Apo = Apolipoprotein; BMI = body mass index; CHD = coronary heart disease; EZ = ezetimibe; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density
lipoprotein cholesterol; hs-CRP = high-sensitivity C-reactive protein; SD = standard deviation; TC = total cholesterol
*Patients who entered a study who were already receiving statin treatment prior to screening
‡presented as median values (robust SD); p-values based on ANOVA model using Tukey scores transformed values with term for gender.
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Page 5 of 11of 12 deaths were reported (5 in the statin group and 7 in
the statin + ezetimibe group) during the course of all 27
studies and none of the deaths were attributed to
treatment.
Discussion
The results of this pooled analysis demonstrated that in
general, the response to statins was similar for both
men and women. Men had slightly greater lipid
responses to the ezetimibe + statin combination com-
pared with women, but the clinical relevance of this is
questionable. When comparing women and men, the
odds were greater for women vs. men in the attainment
of specified LDL-C and apolipoprotein B targets, while
the odds of achieving specified hs-CRP targets was
greater for men vs. women. In the full cohort and in
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Figure 1 Percent change in lipid, lipid ratio, and hs-CRP levels in male and female patients. All between-treatment differences were p <
0.0001 except for Apo A-I, for which the between treatment difference in women was p = 0.0009 and in men was p = 0.0389.
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Figure 2 Percent of patients by sex achieving specified single lipid and hs-CRP levels. Error bars represent standard error.
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Page 6 of 11both sexes, achievement of specified single and dual
lipid levels was greater with statin + ezetimibe vs. statin.
The tolerability profiles were generally similar between
sexes and treatments. The differences reported here are
small. In addition, there was no significant effect of sex
on the changes in the lipid ratios, supporting the per-
spective that the small differences in LDL-C response
observed are not likely to translate into clinically mean-
ingful differences. These findings suggest any potential
sex differences that may exist in response to lipid-lower-
ing therapy and achievement of specified lipid and hs-
CRP levels, should unlikely account for the care gaps
reported in the literature [4,10]. These data should be
considered when planning and assessing such treatment
in men and women.
Analyses of changes in LDL-C by sex subgroups have
been presented in several previous reports and demon-
strated that men and women responded to treatment
similarly to the overall population [11-22]. In those stu-
dies, the subgroups by sex were relatively small; and
although the analyses of change in LDL-C were prespe-
cified, they were not powered to show statistical differ-
ences between the sex subgroups. Moreover, previous
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Figure 3 Percent of patients by sex achieving dual specified lipid and hs-CRP levels. Error bars represent standard error.
Table 3 Adjusted odds ratios and 95% confidence
intervals* in females vs males
Female vs. Male
LDL-C < 100 mg/dL 1.09 (1.02, 1.17)
non-HDL-C < 130 mg/dL 1.03 (0.96, 1.10)
Apo B < 90 mg/dL 1.14 (1.07, 1.22)
hs-CRP < 2 mg/L 0.76 (0.71, 0.82)
hs-CRP < 1 mg/dL 0.86 (0.80, 0.93)
LDL-C < 100 & non-HDL-C < 130 mg/dL 1.07 (1.00, 1.14)
LDL-C < 100 & Apo B < 90 mg/dL 1.11 (1.04, 1.19)
LDL-C < 100 & hs-CRP < 2 mg/L 0.90 (0.84, 0.97)
LDL-C < 100 & hs-CRP < 1 mg/L 0.99 (0.91, 1.07)
Apo = Apolipoprotein; EZ = ezetimibe; LDL-C = low-density lipoprotein
cholesterol; HDL-C = high-density lipoprotein cholesterol; hs-CRP = high-
sensitivity C-reactive protein
*Ratio of the predictive odds of attaining target in female versus male
patients is based on the logistic model with terms for first/second line, sex,
treatment, and baseline value(s).
Table 4 Adjusted odds ratios and 95% confidence
intervals for between-treatment comparisons*
LDL-C < 100 mg/dL 5.29 (4.79, 5.84)
non-HDL-C < 130 mg/dL 5.08 (4.59, 5.61)
Apo B < 90 mg/dL 3.30 (2.98, 3.64)
hs-CRP < 2 mg/L 1.22 (1.12, 1.34)
hs-CRP < 1 mg/dL 1.26 (1.15, 1.39)
LDL-C < 100 & non-HDL-C < 130 mg/dL 5.18 (4.70, 5.70)
LDL-C < 100 & Apo B < 90 mg/dL 3.34 (3.02, 3.69)
LDL-C < 100 & hs-CRP < 2 mg/L 2.52 (2.30, 2.77)
LDL-C < 100 & hs-CRP < 1 mg/L 2.05 (1.84, 2.28)
Apo = Apolipoprotein; EZ = ezetimibe; LDL-C = low-density lipoprotein
cholesterol; HDL-C = high-density lipoprotein cholesterol; hs-CRP = high-
sensitivity C-reactive protein
*Ratio of the predictive odds of attaining target on Statin+EZ versus statin
based on the logistic model with terms for first/second line, treatment, and
baseline value(s).
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Page 7 of 11Table 5 Adverse event summary
Full Cohort Male Female
Adverse events, n
(%)
Statin Statin/EZ Between
treatment p-
value
P-value
for effect
of sex
Statin statin/EZ Between
Treatment
p-value
Statin Statin/EZ Between
treatment
p-value
N = 10517 N = 11714 N = 5380 N = 6129 N = 5137 N = 5585
≥1 3455 (32.9) 3717 (31.7) 0.849 < 0.001 1537
(28.6)
1779
(29.0)
0.173 1918
(37.3)
1938
(34.7)
0.114
Drug related* 833 (7.9) 961 (8.2) 0.181 < 0.001 349 (6.5) 456 (7.4) 0.025 484 (9.4) 505 (9.0) 0.819
Serious 145 (1.4) 187 (1.6) 0.220 0.370 74 (1.4) 107 (1.7) 0.122 71 (1.4) 80 (1.4) 0.091
Serious drug related 6 (0.1) 13 (0.1) 0.148 0.908 2 (0.0) 8 (0.1) 0.075 4 (0.1) 5 (0.1) 0.784
Discontinuations
†
due to AEs
219 (2.1) 263 (2.2) 0.286 < 0.001 91 (1.7) 105 (1.7) 0.828 128 (2.5) 158 (2.8) 0.229
Drug
related*
136 (1.3) 177 (1.5) 0.117 < 0.001 49 (0.9) 69 (1.1) 0.234 87 (1.7) 108 (1.9) 0.288
Serious 34 (0.3) 38 (0.3) 0.906 0.320 18 (0.3) 23 (0.4) 0.659 16 (0.3) 15 (0.3) 0.746
Serious
drug
related
6 (0.1) 7 (0.1) 0.864 0.749 2 (0.0) 4 (0.1) 0.485 4 (0.1) 3 (0.1) 0.689
Deaths 5 (0.0) 7 (0.1) 0.702 0.655 4 (0.1) 3 (0.0) 0.582 1 (0.0) 4 (0.1) 0.197
Gastrointestinal-
related
‡
861 (8.2) 889 (7.6) 0.367 < 0.001 339 (6.3) 390 (6.4) 0.636 522 (10.2) 499 (8.9) 0.113
Gallbladder-
related
§
9 (0.1) 11 (0.1) 0.824 0.014 2 (0.0) 3 (0.0) 0.754 7 (0.1) 8 (0.1) 0.940
Allergic reaction
or rash
║
175 (1.7) 213 (1.8) 0.194 < 0.001 70 (1.3) 90 (1.5) 0.326 105 (2.0) 123 (2.2) 0.382
Hepatitis-
related
¶
24 (0.2) 39 (0.3) 0.079 0.030 13 (0.2) 27 (0.4) 0.038 11 (0.2) 12 (0.2) 0.858
ALT ≥ 3 × ULN,
consecutive, m/n (%)
31/10341
(0.3)
50/11512
(0.4)
0.519 0.241 15/5289
(0.3)
34/6031
(0.6)
0.111 16/5052
(0.3)
16/5481
(0.3)
0.611
AST ≥ 3 × ULN,
consecutive, m/n (%)
23/10342
(0.2)
30/11512
(0.3)
0.087 0.100 7/5290
(0.1)
16/6031
(0.3)
0.018 16/5052
(0.3)
14/5481
(0.3)
0.873
ALT or AST ≥3×
ULN, consecutive,
m/n (%)
36/10342
(0.3)
64/11512
(0.6)
0.018 0.185 17/5290
(0.3)
41/6031
(0.7)
0.006 19/5052
(0.4)
23/5481
(0.4)
0.649
CK ≥ 10 × ULN, m/n
(%)
13/10342
(0.1)
9/11514
(0.1)
0.337 0.028 9/5290
(0.2)
7/6033
(0.1)
0.543 4/5052
(0.1)
2/5481
(0.0)
0.395
Myopathy
#, m/n (%) 4/10342
(0.04)
3/11512
(0.03)
0.667 0.699 2/5290
(0.04)
2/6031
(0.02)
0.985 2/5052
(0.04)
1/5481
(0.02)
0.517
Rhabdomyolysis^,
m/n (%)
0/10342
(0.00)
0/11512
(0.00)
N/A N/A 0/5290
(0.00)
0/6031
(0.00)
N/A 0/5052
(0.00)
0/5481
(0.00)
N/A
ALT = alanine aminotransferase, ALT = aspartate aminotransferase, CK = creatine kinase ULN = upper limit of normal
% = m/n × 100 = (number of patients within the AE category/number of treated patients) × 100
*Determined by the investigator to be related to the drug
†Study medication withdrawn
‡For gastrointestinal-related clinical adverse events, the preferred terms (preferred Medra terms) were pre-identified for collective review, including e.g.
abdominal discomfort, abdominal distension, abdominal pain, abdominal tenderness, colitis, colonic polyp, constipation, dental caries, dental discomfort,
diarrhoea, diverticulum, duodenitis, dyspepsiea, dysphagia, erosive duodenitis, faeces discolored, flatulence, flood poisoning, gastitis, gastoesophageal reflux
disease, gingival pain, haemorrhoids, hiatus hernia, nausea, oesophageal stenosis, rectal haemorrhage, tooth loss, toothache, and vomiting.
§For gallbladder-related clinical adverse events the preferred terms (preferred Medra terms) were pre-identified for collective review, including e.g. bile duct
obstruction, bile duct stenosis, bile duct stone, biliary colic, cholangitis, cholecystectomy, cholecystitis, cholelithiasis, gallbladder disorder, and gallbladder
perforation
║For allergic reaction or rash the preferred terms (preferred Medra terms) were pre-identified for collective review, including e.g. analphylaxis, angioedema,
dermatitis, dermagraphism, drug hypersensitivity, eczema, eosinophilia, erythema, face oedema, hypersensitivity, palmar erythema, periorbital oedema,
photodermatosis, photosensitivity, pigmentation disorder, pruritis, rash, rosacea, skin disorder, skin exfoliation, skin hyperpigmentation, skin inflammation, skin
lesion, subcutaneious nodule, systemic lups erythematosus rash, and urticaria
¶In addition to review of the effects of ezetimibe + statin on laboratory parameters associated with liver function, potentially “hepatitis-related” clinical adverse
event terms (preferred Medra terms) were pre-identified for collective review, e.g., cholestasis, hepatic necrosis, hepatocellular injury, cytolytic hepatitis, hepatitis,
hepatomegaly, hepatic cyst, hepatitis cholestatic, jaundice, hepatic failure, hepatitis fulminant, jaundice cholestatic, hepatic lesion, and, hepatitis infectious.
#Myopathy is defined as CK elevation > 10XULN with associated muscle symptoms with no other explanatory cause.
^Rhabdomyolysis is defined as myopathy with associated evidence of renal damage.
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Page 8 of 11reports of individual studies have demonstrated no signif-
icant treatment by sex interactions for LDL-C target
attainment [23-25]. The results in the current pooled
analysis showed that women are ~9% more likely to
achieve LDL-C < 100 mg/dL than men if they were in the
same first-line or second-line study with the same treat-
ment and similar baseline LDL-C. It is important to note
that this analysis was a comparison of all women vs. all
men attaining LDL-C targets, and was not a between-
treatment comparison. This result may seem unusual in
light of the slightly greater LDL-C reductions observed in
men vs. women with ezetimibe + statin and higher base-
line LDL-C levels observed in women vs. men. However,
the model accounted for baseline factors, including LDL-
C level, first-line or second-line study, and treatment.
Since the model accounts for the other factors, such as
study type, the presence of diabetes or CHD, and baseline
LDL-C, further study may elucidate the factors associated
with greater achievement of lipid targets.
Also of interest in the current analysis were the differ-
ences in the odds of achieving specified lipid and hs-
CRP levels between the sexes. There were small but sig-
nificant differences between men and women in the
odds of attaining single specified apolipoprotein B and
hs-CRP levels; the most notable of these differences
being the greater odds for men vs. women achieving
both specified levels of hs-CRP. The magnitude of dif-
ference between treatment groups for attainment of spe-
cified hs-CRP levels was relatively small compared with
other lipid levels, and there were clear differences
between the sexes in achievement of both specified hs-
CRP levels. Higher baseline levels of hs-CRP in women
could also play a role in lower achievement in women
vs. men. One could speculate that the higher levels of
hs-CRP in women, both at baseline and study end,
could be due to the higher prevalence of metabolic syn-
drome and obesity in women, the presence of which has
been associated with increased levels of hs-CRP and
other inflammatory markers [26].
Lipid-lowering treatment reduces coronary events [27],
although the consistency of this effect in women has
been controversial until recently [28,29]. Stronger con-
t e m p o r a r yd a t ah a v ep r o v i d e ds o m ee v i d e n c et o w a r d
answers to that debate. A meta-analysis of primary pre-
vention trials that included sex-specific clinical out-
comes in CVD demonstrated that cardiovascular events
were reduced by about one-third in women after 12
months of statin treatment, during which subjects
experienced a 51 mg/dL reduction from baseline in
LDL-C [7]. Similar relative risk reductions were
observed in men. The Cholesterol Treatment Trialists’
(CTT) Collaboration showed that further reductions in
LDL cholesterol produce definite further reductions in
the incidence of cardiovascular events in the overall
population, with a significant proportional risk reduction
of 17% (p < 0.001) per 39 mg/dL reduction in LDL-C
among women in first major vascular events [30]. Taken
together, these data support the utility of intensive lipid
lowering for reducing the risk of cardiovascular events
in both men and women. Though the ultimate assess-
ment of clinical impact of lipid-lowering therapy sup-
ported by ezetimibe-related therapy awaits results of
IMPROVE-IT, [31] results from SEAS and SHARP
describe lower rates of ischemic cardiac events with eze-
timibe-simvastatin therapy in subjects with aortic steno-
sis and chronic kidney disease, respectively [32-34].
Both treatments were generally well tolerated in the
overall population and in both sexes. This is consistent
with previous reports, which have shown generally com-
parable safety and tolerability profiles with statin mono-
therapy and ezetimibe + statin coadministration
treatment [35,36]. In conclusion, the results of the pre-
sent study underscore the utility of lipid-lowering ther-
apy in women. The small sex-related differences in
lipid-lowering therapy may not be clinically meaningful
and underscore the ongoing need for appropriate man-
agement of lipid levels in women.
Abbreviations
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